The pharmacokinetic interaction between mycophenolic acid and cyclosporine revisited: a commentary on “Mycophenolic acid glucuronide is transported by multidrug resistance-associated protein 2 and this transport is not inhibited by cyclosporine, tacrolimus or sirolimus”

References

• Bullingham RE, Nicholls AJ, Kamm BR. (1998). Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 34:429–55
   PubMed Web of Science ®Google Scholar
• Fehrenbach T, Cui Y, Faulstich H, Keppler D. (2003). Characterization of the transport of the bicyclic peptide phalloidin by human hepatic transport proteins. Naunyn Schmiedebergs Arch Pharmacol 368:415–20
   PubMed Web of Science ®Google Scholar
• Hesselink DA, van Hest RM, Mathot RA, et al. (2005). Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 5:987–94
   PubMed Web of Science ®Google Scholar
• Hubner GI, Eismann R, Sziegoleit W. (1999). Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients. Ther Drug Monit 21:536–9
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Saitoh H, Kobayashi M, et al. (2004). Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J Pharmacol Exp Ther 309:1029–35
   PubMed Web of Science ®Google Scholar
• Lemahieu WP, Hermann M, Asberg A, et al. (2005). Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am J Transplant 5:2236–43
   PubMed Web of Science ®Google Scholar
• Patel CG, Ogasawara K, Akhlaghi F. (2012). Mycophenolic acid glucuronide is transported by multidrug resistance-associated protein 2 and this transport is not inhibited by cyclosporine, tacrolimus or sirolimus. Xenobiotica . DOI: 10.3109/00498254.2012.713531
   Web of Science ®Google Scholar
• Picard N, Levoir L, Lamoureux F, et al. (2011). Interaction of sirolimus and everolimus with hepatic and intestinal organic anion-transporting polypeptide transporters. Xenobiotica 41:752–7
   PubMed Web of Science ®Google Scholar
• Picard N, Yee SW, Woillard JB, et al. (2010). The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. Clin Pharmacol Ther 87:100–8
   PubMed Web of Science ®Google Scholar
• Pou L, Brunet M, Cantarell C, et al. (2001). Mycophenolic acid plasma concentrations: influence of comedication. Ther Drug Monit 23:35–8
   PubMed Web of Science ®Google Scholar
• Schaub TP, Kartenbeck J, Konig J, et al. (1999). Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma. J Am Soc Nephrol 10:1159–69
   PubMed Web of Science ®Google Scholar
• Shitara Y, Itoh T, Sato H, et al. (2003). Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 304:610–16
   PubMed Web of Science ®Google Scholar
• Shitara Y, Takeuchi K, Nagamatsu Y, et al. (2012). Long-lasting inhibitory effects of cyclosporin A, but not tacrolimus, on OATP1B1- and OATP1B3-mediated uptake. Drug Metab Pharmacokinet 27:368–78
   PubMed Web of Science ®Google Scholar
• Smak Gregoor PJ, van Gelder T, Hesse CJ, et al. (1999). Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study. Nephrol Dial Transplant 14:706–8
   PubMed Web of Science ®Google Scholar
• Treiber A, Schneiter R, Hausler S, Stieger B. (2007). Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos 35:1400–7
   PubMed Web of Science ®Google Scholar
• Uwai Y, Motohashi H, Tsuji Y, et al. (2007). Interaction and transport characteristics of mycophenolic acid and its glucuronide via human organic anion transporters hOAT1 and hOAT3. Biochem Pharmacol 74:161–8
   PubMed Web of Science ®Google Scholar
• van Gelder T, Klupp J, Barten MJ, et al. (2001). Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 23:119–28
   PubMed Web of Science ®Google Scholar
• Westley IS, Brogan LR, Morris RG, et al. (2006). Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine. Drug Metab Dispos 34:261–6
   PubMed Web of Science ®Google Scholar
• Wolff NA, Burckhardt BC, Burckhardt G, et al. (2007). Mycophenolic acid (MPA) and its glucuronide metabolites interact with transport systems responsible for excretion of organic anions in the basolateral membrane of the human kidney. Nephrol Dial Transplant 22:2497–503
   PubMed Web of Science ®Google Scholar
• Zucker K, Rosen A, Tsaroucha A, et al. (1997). Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl Immunol 5:225–32
   PubMed Web of Science ®Google Scholar